Comparison of Biomarker Modulation by Inhibition of EGFR and/or Src Family Kinases Using Erlotinib and Dasatinib in Head and Neck Lung Cancers.
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2016
At a glance
- Drugs Dasatinib (Primary) ; Erlotinib (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 17 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 05 May 2014 Planned End Date changed from 1 Oct 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History